Veru Reaches Agreement With FDA On New Phase 3 Clinical Trial For Sabizabulin For Broader Indication: Hospitalized Adult Patients With Any Type Of Viral Acute Respiratory Distress Syndrome
Portfolio Pulse from Benzinga Newsdesk
Veru has reached an agreement with the FDA to conduct a Phase 3 clinical trial for Sabizabulin for a broader indication, including all hospitalized adult patients with any type of virus-induced Acute Respiratory Distress Syndrome (ARDS). The study, which could begin as early as Q4 2023, will replace the second confirmatory Phase 3 COVID-19 study.
September 26, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Veru's agreement with the FDA to conduct a broader Phase 3 trial for Sabizabulin could potentially increase the drug's market. However, the trial's start date in late 2023 may delay potential revenues.
The news is directly related to Veru and its product, Sabizabulin. The broader indication for the drug could potentially increase its market, which could positively impact Veru's stock. However, the late start of the trial could delay potential revenues from the drug, which could have a neutral to negative impact on the stock in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100